 Jonathan Samet
Concepts (994)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Air Pollution | 73 | 2025 | 321 | 11.470 |
Why?
| | Smoking | 107 | 2018 | 1576 | 9.000 |
Why?
| | Air Pollutants | 73 | 2025 | 428 | 7.700 |
Why?
| | Tobacco Smoke Pollution | 52 | 2016 | 238 | 7.420 |
Why?
| | Environmental Exposure | 74 | 2025 | 579 | 7.380 |
Why?
| | Public Health | 54 | 2025 | 554 | 7.210 |
Why?
| | Neoplasms, Radiation-Induced | 33 | 2025 | 98 | 6.050 |
Why?
| | Smoking Prevention | 25 | 2021 | 170 | 5.110 |
Why?
| | Air Pollution, Indoor | 30 | 2024 | 180 | 4.490 |
Why?
| | Lung Neoplasms | 68 | 2026 | 2554 | 4.480 |
Why?
| | Epidemiology | 20 | 2020 | 33 | 4.220 |
Why?
| | Particulate Matter | 37 | 2025 | 330 | 4.190 |
Why?
| | Global Health | 22 | 2020 | 384 | 4.010 |
Why?
| | Tobacco Industry | 19 | 2018 | 26 | 3.630 |
Why?
| | Smoking Cessation | 26 | 2021 | 431 | 3.630 |
Why?
| | Tobacco Products | 17 | 2024 | 91 | 3.620 |
Why?
| | Occupational Exposure | 27 | 2025 | 346 | 3.470 |
Why?
| | Respiratory Tract Diseases | 29 | 2017 | 180 | 3.300 |
Why?
| | Radon | 28 | 2024 | 44 | 3.210 |
Why?
| | Mortality | 31 | 2024 | 359 | 3.070 |
Why?
| | Neoplasms | 34 | 2025 | 2731 | 3.050 |
Why?
| | Environmental Health | 14 | 2021 | 38 | 2.920 |
Why?
| | Occupational Diseases | 19 | 2024 | 160 | 2.770 |
Why?
| | Environmental Monitoring | 28 | 2024 | 369 | 2.550 |
Why?
| | Humans | 443 | 2026 | 141284 | 2.500 |
Why?
| | Uranium | 18 | 2025 | 27 | 2.490 |
Why?
| | Carcinogens | 9 | 2022 | 125 | 2.240 |
Why?
| | Electronic Nicotine Delivery Systems | 15 | 2024 | 106 | 2.210 |
Why?
| | United States | 124 | 2026 | 15298 | 2.090 |
Why?
| | Health Policy | 19 | 2020 | 385 | 2.030 |
Why?
| | Cardiovascular Diseases | 29 | 2017 | 2091 | 2.010 |
Why?
| | Ozone | 11 | 2024 | 133 | 1.890 |
Why?
| | Nuclear Weapons | 2 | 2025 | 7 | 1.830 |
Why?
| | Mining | 18 | 2025 | 33 | 1.820 |
Why?
| | Dronabinol | 3 | 2025 | 240 | 1.670 |
Why?
| | Epidemiologic Methods | 20 | 2012 | 94 | 1.620 |
Why?
| | Risk Assessment | 42 | 2020 | 3522 | 1.520 |
Why?
| | Epidemiologic Studies | 9 | 2024 | 68 | 1.490 |
Why?
| | Research | 13 | 2014 | 434 | 1.460 |
Why?
| | Politics | 7 | 2024 | 92 | 1.450 |
Why?
| | United States Environmental Protection Agency | 10 | 2020 | 28 | 1.420 |
Why?
| | Research Design | 15 | 2025 | 1105 | 1.380 |
Why?
| | History, 20th Century | 15 | 2025 | 324 | 1.370 |
Why?
| | Tobacco Use Disorder | 8 | 2015 | 237 | 1.310 |
Why?
| | Environmental Policy | 3 | 2020 | 6 | 1.310 |
Why?
| | Biomedical Research | 11 | 2020 | 684 | 1.230 |
Why?
| | Respiration Disorders | 7 | 2022 | 79 | 1.210 |
Why?
| | Forecasting | 13 | 2020 | 383 | 1.190 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 10 | 2025 | 1039 | 1.150 |
Why?
| | Risk Factors | 79 | 2025 | 10490 | 1.150 |
Why?
| | Developing Countries | 7 | 2014 | 308 | 1.140 |
Why?
| | Climate Change | 7 | 2023 | 187 | 1.130 |
Why?
| | Ventilation | 4 | 2024 | 44 | 1.110 |
Why?
| | Urban Health | 8 | 2014 | 95 | 1.070 |
Why?
| | Cost of Illness | 5 | 2018 | 311 | 1.070 |
Why?
| | Cannabis | 2 | 2025 | 510 | 1.060 |
Why?
| | Lung Diseases | 12 | 2018 | 779 | 1.040 |
Why?
| | Menthol | 5 | 2021 | 13 | 1.020 |
Why?
| | Nicotine | 18 | 2016 | 339 | 1.020 |
Why?
| | Causality | 8 | 2016 | 131 | 1.010 |
Why?
| | Models, Statistical | 17 | 2016 | 669 | 1.010 |
Why?
| | Inhalation Exposure | 7 | 2017 | 113 | 1.010 |
Why?
| | Nuclear Warfare | 4 | 2024 | 10 | 1.010 |
Why?
| | Cohort Studies | 38 | 2025 | 5809 | 0.980 |
Why?
| | Guidelines as Topic | 4 | 2020 | 269 | 0.940 |
Why?
| | International Agencies | 5 | 2022 | 32 | 0.940 |
Why?
| | Maternal Exposure | 5 | 2016 | 201 | 0.940 |
Why?
| | Cotinine | 10 | 2014 | 78 | 0.930 |
Why?
| | Health Status Disparities | 3 | 2019 | 303 | 0.920 |
Why?
| | History, 21st Century | 8 | 2025 | 218 | 0.890 |
Why?
| | Tuberculosis | 2 | 2019 | 281 | 0.870 |
Why?
| | Cell Phone | 3 | 2014 | 82 | 0.860 |
Why?
| | Particle Size | 19 | 2014 | 403 | 0.860 |
Why?
| | Male | 153 | 2025 | 70140 | 0.860 |
Why?
| | Female | 153 | 2025 | 75814 | 0.850 |
Why?
| | Asbestos | 5 | 2019 | 35 | 0.850 |
Why?
| | Government Regulation | 5 | 2017 | 37 | 0.850 |
Why?
| | Sleep Apnea Syndromes | 6 | 2016 | 90 | 0.850 |
Why?
| | Vaping | 6 | 2024 | 63 | 0.840 |
Why?
| | Environmental Pollutants | 3 | 2019 | 158 | 0.840 |
Why?
| | Cause of Death | 12 | 2016 | 449 | 0.820 |
Why?
| | Adult | 104 | 2025 | 39319 | 0.820 |
Why?
| | Population Health | 1 | 2024 | 45 | 0.820 |
Why?
| | Health Equity | 3 | 2021 | 107 | 0.810 |
Why?
| | Conservation of Natural Resources | 3 | 2020 | 127 | 0.810 |
Why?
| | Aged | 88 | 2025 | 24836 | 0.780 |
Why?
| | Environmental Pollution | 2 | 2020 | 21 | 0.780 |
Why?
| | Public Policy | 11 | 2015 | 75 | 0.780 |
Why?
| | Advisory Committees | 4 | 2020 | 214 | 0.770 |
Why?
| | Urban Population | 12 | 2009 | 482 | 0.770 |
Why?
| | Vehicle Emissions | 7 | 2023 | 65 | 0.760 |
Why?
| | Child Health | 1 | 2024 | 153 | 0.760 |
Why?
| | Flavoring Agents | 3 | 2016 | 13 | 0.740 |
Why?
| | United States Food and Drug Administration | 5 | 2017 | 197 | 0.710 |
Why?
| | Incidence | 20 | 2024 | 2809 | 0.710 |
Why?
| | Asthma | 14 | 2014 | 1911 | 0.710 |
Why?
| | Middle Aged | 97 | 2025 | 34658 | 0.700 |
Why?
| | Brachial Plexus Neuropathies | 1 | 2021 | 19 | 0.690 |
Why?
| | Leadership | 6 | 2024 | 388 | 0.690 |
Why?
| | Brachial Plexus | 1 | 2021 | 34 | 0.680 |
Why?
| | Abnormalities, Radiation-Induced | 1 | 2020 | 1 | 0.680 |
Why?
| | Public Health Practice | 3 | 2019 | 67 | 0.670 |
Why?
| | Heart Diseases | 5 | 2013 | 337 | 0.670 |
Why?
| | Tobacco Smoking | 1 | 2020 | 25 | 0.670 |
Why?
| | Magnetic Resonance Imaging | 8 | 2026 | 3734 | 0.670 |
Why?
| | Anniversaries and Special Events | 1 | 2020 | 17 | 0.670 |
Why?
| | New Mexico | 37 | 2002 | 101 | 0.670 |
Why?
| | Disease | 2 | 2019 | 98 | 0.660 |
Why?
| | Science | 2 | 2022 | 52 | 0.660 |
Why?
| | Social Control, Formal | 1 | 2020 | 11 | 0.640 |
Why?
| | Research Support as Topic | 6 | 2014 | 81 | 0.620 |
Why?
| | Smoke | 4 | 2020 | 148 | 0.620 |
Why?
| | Smokers | 1 | 2020 | 146 | 0.620 |
Why?
| | Health Care Costs | 3 | 2014 | 417 | 0.610 |
Why?
| | Risk | 22 | 2016 | 903 | 0.610 |
Why?
| | Radiation Exposure | 3 | 2025 | 60 | 0.610 |
Why?
| | Epidemiologists | 1 | 2019 | 5 | 0.610 |
Why?
| | Viruses | 1 | 2021 | 163 | 0.610 |
Why?
| | Filtration | 3 | 2017 | 68 | 0.600 |
Why?
| | Carcinogens, Environmental | 4 | 2015 | 14 | 0.600 |
Why?
| | Mexico | 15 | 2019 | 229 | 0.580 |
Why?
| | Morbidity | 7 | 2017 | 320 | 0.570 |
Why?
| | Minority Groups | 4 | 2017 | 278 | 0.570 |
Why?
| | Indians, North American | 14 | 1995 | 655 | 0.560 |
Why?
| | International Cooperation | 10 | 2012 | 195 | 0.560 |
Why?
| | Obesity, Abdominal | 1 | 2018 | 44 | 0.560 |
Why?
| | Professional Competence | 4 | 2019 | 96 | 0.550 |
Why?
| | Chernobyl Nuclear Accident | 1 | 2017 | 5 | 0.550 |
Why?
| | Publications | 2 | 2015 | 48 | 0.550 |
Why?
| | Smoke-Free Policy | 2 | 2018 | 13 | 0.550 |
Why?
| | Environmental Illness | 1 | 2017 | 3 | 0.550 |
Why?
| | Respiratory Tract Infections | 6 | 2024 | 388 | 0.540 |
Why?
| | Proportional Hazards Models | 12 | 2025 | 1268 | 0.540 |
Why?
| | Climate | 5 | 2013 | 89 | 0.530 |
Why?
| | Saliva | 6 | 2014 | 246 | 0.530 |
Why?
| | Japan | 6 | 2025 | 134 | 0.530 |
Why?
| | Age Factors | 20 | 2020 | 3295 | 0.520 |
Why?
| | Cyclonic Storms | 1 | 2018 | 38 | 0.520 |
Why?
| | Biomarkers, Tumor | 4 | 2025 | 1250 | 0.520 |
Why?
| | Air Pollutants, Radioactive | 5 | 2006 | 8 | 0.510 |
Why?
| | Harm Reduction | 4 | 2021 | 38 | 0.510 |
Why?
| | Chronic Disease | 4 | 2015 | 1807 | 0.500 |
Why?
| | Breast Neoplasms | 12 | 2009 | 2246 | 0.500 |
Why?
| | Evidence-Based Practice | 5 | 2018 | 229 | 0.500 |
Why?
| | Pandemics | 3 | 2024 | 1655 | 0.500 |
Why?
| | Organizational Policy | 2 | 2014 | 76 | 0.490 |
Why?
| | Cities | 6 | 2024 | 137 | 0.490 |
Why?
| | World Health Organization | 7 | 2016 | 103 | 0.490 |
Why?
| | Perinatal Death | 1 | 2016 | 26 | 0.490 |
Why?
| | Biological Transport, Active | 1 | 2016 | 70 | 0.490 |
Why?
| | Radiation Injuries | 1 | 2017 | 148 | 0.490 |
Why?
| | Nitrogen Dioxide | 7 | 2023 | 45 | 0.490 |
Why?
| | Prospective Studies | 22 | 2024 | 7805 | 0.480 |
Why?
| | Hospitalization | 9 | 2009 | 2264 | 0.480 |
Why?
| | Prevalence | 18 | 2020 | 2795 | 0.480 |
Why?
| | Stillbirth | 1 | 2016 | 74 | 0.470 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 2016 | 36 | 0.470 |
Why?
| | Obesity | 7 | 2018 | 3007 | 0.470 |
Why?
| | Hazardous Substances | 4 | 2015 | 15 | 0.470 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 288 | 0.470 |
Why?
| | Cigarette Smoking | 4 | 2020 | 101 | 0.460 |
Why?
| | Population Surveillance | 10 | 2018 | 481 | 0.460 |
Why?
| | gamma-Glutamyltransferase | 1 | 2015 | 42 | 0.460 |
Why?
| | Tobacco Use | 1 | 2016 | 65 | 0.460 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 374 | 0.460 |
Why?
| | Bone Diseases | 1 | 2016 | 65 | 0.460 |
Why?
| | Coronavirus Infections | 1 | 2020 | 370 | 0.450 |
Why?
| | Organizations | 1 | 2015 | 26 | 0.450 |
Why?
| | Time Factors | 31 | 2019 | 6951 | 0.450 |
Why?
| | Health Services Accessibility | 4 | 2017 | 1030 | 0.450 |
Why?
| | Body Mass Index | 7 | 2016 | 2390 | 0.450 |
Why?
| | Nicotinic Agonists | 3 | 2013 | 136 | 0.450 |
Why?
| | Dose-Response Relationship, Radiation | 5 | 2011 | 143 | 0.450 |
Why?
| | Aged, 80 and over | 24 | 2025 | 7948 | 0.440 |
Why?
| | Republic of Korea | 6 | 2019 | 41 | 0.440 |
Why?
| | Soft Tissue Neoplasms | 2 | 2026 | 120 | 0.440 |
Why?
| | Epidemics | 1 | 2016 | 95 | 0.440 |
Why?
| | Health Facility Administration | 1 | 2014 | 7 | 0.430 |
Why?
| | Social Discrimination | 1 | 2014 | 12 | 0.430 |
Why?
| | Case-Control Studies | 21 | 2016 | 3577 | 0.430 |
Why?
| | Alkaloids | 1 | 2014 | 28 | 0.420 |
Why?
| | Linear Models | 9 | 2018 | 855 | 0.420 |
Why?
| | Health Promotion | 6 | 2013 | 749 | 0.410 |
Why?
| | Odds Ratio | 15 | 2019 | 1057 | 0.410 |
Why?
| | Data Collection | 9 | 2019 | 655 | 0.410 |
Why?
| | Carbon Monoxide | 5 | 2022 | 83 | 0.410 |
Why?
| | Behavior | 1 | 2014 | 92 | 0.410 |
Why?
| | Tuberculosis, Pulmonary | 2 | 2016 | 129 | 0.410 |
Why?
| | Lung | 12 | 2016 | 4051 | 0.410 |
Why?
| | Bronchi | 7 | 2000 | 261 | 0.400 |
Why?
| | Aerosols | 5 | 2021 | 177 | 0.400 |
Why?
| | Vanadium | 7 | 2009 | 10 | 0.390 |
Why?
| | Europe | 8 | 2024 | 408 | 0.390 |
Why?
| | Adolescent Behavior | 4 | 2016 | 538 | 0.390 |
Why?
| | Abortion, Spontaneous | 1 | 2014 | 116 | 0.390 |
Why?
| | Personnel Selection | 1 | 2014 | 86 | 0.390 |
Why?
| | Hot Temperature | 3 | 2014 | 405 | 0.380 |
Why?
| | Workplace | 5 | 2011 | 265 | 0.380 |
Why?
| | Medicare | 7 | 2012 | 802 | 0.380 |
Why?
| | Child | 35 | 2025 | 22390 | 0.380 |
Why?
| | Australia | 6 | 2024 | 287 | 0.380 |
Why?
| | Preventive Medicine | 1 | 2012 | 40 | 0.370 |
Why?
| | Canada | 4 | 2024 | 420 | 0.370 |
Why?
| | Regression Analysis | 10 | 2018 | 1013 | 0.370 |
Why?
| | Life Expectancy | 1 | 2013 | 71 | 0.370 |
Why?
| | Exercise | 4 | 2021 | 2113 | 0.370 |
Why?
| | Sex Distribution | 7 | 2019 | 381 | 0.370 |
Why?
| | Lead | 6 | 2015 | 71 | 0.370 |
Why?
| | Surveys and Questionnaires | 27 | 2024 | 5948 | 0.370 |
Why?
| | Child Welfare | 3 | 2004 | 229 | 0.370 |
Why?
| | Adolescent | 40 | 2025 | 22116 | 0.370 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2019 | 653 | 0.360 |
Why?
| | Research Report | 1 | 2012 | 80 | 0.360 |
Why?
| | Health Surveys | 9 | 2017 | 511 | 0.360 |
Why?
| | Diabetes Mellitus | 2 | 2019 | 1078 | 0.360 |
Why?
| | Meningioma | 2 | 2010 | 89 | 0.360 |
Why?
| | Genetic Predisposition to Disease | 5 | 2014 | 2366 | 0.360 |
Why?
| | Adenocarcinoma | 4 | 2017 | 897 | 0.360 |
Why?
| | Respiratory Sounds | 4 | 2024 | 109 | 0.360 |
Why?
| | Korea | 5 | 2015 | 17 | 0.350 |
Why?
| | Data Interpretation, Statistical | 5 | 2008 | 374 | 0.350 |
Why?
| | Miners | 2 | 2022 | 3 | 0.350 |
Why?
| | Coal | 3 | 2022 | 19 | 0.350 |
Why?
| | Drug and Narcotic Control | 1 | 2011 | 26 | 0.340 |
Why?
| | Leukocyte Count | 2 | 2005 | 317 | 0.340 |
Why?
| | Heat Stress Disorders | 2 | 2002 | 82 | 0.340 |
Why?
| | Idiopathic Pulmonary Fibrosis | 2 | 2015 | 666 | 0.340 |
Why?
| | China | 8 | 2012 | 220 | 0.340 |
Why?
| | Copying Processes | 1 | 2010 | 1 | 0.340 |
Why?
| | Americas | 3 | 2019 | 26 | 0.330 |
Why?
| | Veterans Disability Claims | 1 | 2010 | 3 | 0.330 |
Why?
| | Mass Screening | 1 | 2019 | 1309 | 0.330 |
Why?
| | Dose-Response Relationship, Drug | 7 | 2016 | 2047 | 0.330 |
Why?
| | Wildfires | 2 | 2021 | 40 | 0.330 |
Why?
| | Seasons | 10 | 2021 | 547 | 0.320 |
Why?
| | Societies, Medical | 9 | 2026 | 859 | 0.320 |
Why?
| | Education, Public Health Professional | 2 | 2008 | 8 | 0.320 |
Why?
| | Brazil | 4 | 2019 | 168 | 0.320 |
Why?
| | Congresses as Topic | 5 | 2018 | 223 | 0.320 |
Why?
| | Career Choice | 2 | 2010 | 233 | 0.320 |
Why?
| | September 11 Terrorist Attacks | 2 | 2007 | 30 | 0.320 |
Why?
| | Air Microbiology | 3 | 2024 | 47 | 0.320 |
Why?
| | Young Adult | 21 | 2025 | 13727 | 0.310 |
Why?
| | Child, Preschool | 19 | 2024 | 11511 | 0.310 |
Why?
| | Rural Health | 2 | 2007 | 85 | 0.310 |
Why?
| | Product Packaging | 3 | 2020 | 6 | 0.310 |
Why?
| | Health | 4 | 2018 | 83 | 0.310 |
Why?
| | Carcinogenesis | 2 | 2022 | 218 | 0.310 |
Why?
| | Cystic Fibrosis | 3 | 2014 | 1124 | 0.300 |
Why?
| | Hair | 6 | 2014 | 89 | 0.300 |
Why?
| | Tobacco, Smokeless | 4 | 2016 | 13 | 0.300 |
Why?
| | Sex Factors | 13 | 2015 | 2055 | 0.290 |
Why?
| | Blood Glucose | 4 | 2022 | 2286 | 0.290 |
Why?
| | Deception | 1 | 2008 | 19 | 0.290 |
Why?
| | Housing | 7 | 2011 | 146 | 0.290 |
Why?
| | Expert Testimony | 2 | 2006 | 41 | 0.290 |
Why?
| | Radiology Information Systems | 2 | 2025 | 33 | 0.280 |
Why?
| | Women's Health | 1 | 2010 | 308 | 0.280 |
Why?
| | Alcohol Drinking | 3 | 2005 | 834 | 0.280 |
Why?
| | Glioma | 2 | 2010 | 418 | 0.280 |
Why?
| | Commerce | 4 | 2021 | 74 | 0.270 |
Why?
| | Effect Modifier, Epidemiologic | 1 | 2007 | 9 | 0.270 |
Why?
| | Information Dissemination | 2 | 2010 | 209 | 0.270 |
Why?
| | Biomarkers | 10 | 2017 | 4180 | 0.270 |
Why?
| | Air Pollutants, Occupational | 4 | 2008 | 41 | 0.270 |
Why?
| | Spirometry | 4 | 2016 | 260 | 0.270 |
Why?
| | Evidence-Based Medicine | 6 | 2014 | 717 | 0.270 |
Why?
| | Registries | 8 | 2022 | 2205 | 0.260 |
Why?
| | Musculoskeletal Diseases | 2 | 2025 | 87 | 0.260 |
Why?
| | Construction Materials | 1 | 2007 | 17 | 0.260 |
Why?
| | Environment, Controlled | 2 | 2006 | 23 | 0.260 |
Why?
| | Professional Role | 3 | 2019 | 164 | 0.260 |
Why?
| | Foundations | 3 | 2018 | 28 | 0.250 |
Why?
| | Education | 2 | 2018 | 107 | 0.250 |
Why?
| | Bias | 6 | 2018 | 208 | 0.250 |
Why?
| | Ontario | 3 | 2019 | 95 | 0.250 |
Why?
| | Marketing | 4 | 2021 | 24 | 0.250 |
Why?
| | Growth Disorders | 1 | 2007 | 87 | 0.250 |
Why?
| | Social Environment | 2 | 2019 | 294 | 0.240 |
Why?
| | Tomography, X-Ray Computed | 2 | 2007 | 2765 | 0.240 |
Why?
| | Academies and Institutes | 4 | 2022 | 54 | 0.240 |
Why?
| | Sarcoma, Small Cell | 1 | 2025 | 2 | 0.240 |
Why?
| | Los Angeles | 4 | 2024 | 75 | 0.240 |
Why?
| | Publishing | 2 | 2014 | 109 | 0.240 |
Why?
| | Radon Daughters | 5 | 2022 | 5 | 0.240 |
Why?
| | RNA-Binding Protein FUS | 1 | 2025 | 14 | 0.240 |
Why?
| | RNA-Binding Protein EWS | 1 | 2025 | 28 | 0.240 |
Why?
| | National Institutes of Health (U.S.) | 3 | 2018 | 132 | 0.240 |
Why?
| | Thoracic Neoplasms | 1 | 2026 | 39 | 0.240 |
Why?
| | Metals | 4 | 1999 | 140 | 0.240 |
Why?
| | Neurofibroma, Plexiform | 1 | 2025 | 12 | 0.230 |
Why?
| | Teaching | 1 | 2008 | 233 | 0.230 |
Why?
| | Retrospective Studies | 13 | 2025 | 16447 | 0.230 |
Why?
| | Respiratory System | 2 | 2021 | 155 | 0.230 |
Why?
| | NFATC Transcription Factors | 1 | 2025 | 94 | 0.230 |
Why?
| | Anemia | 1 | 2007 | 175 | 0.230 |
Why?
| | Bayes Theorem | 5 | 2006 | 414 | 0.230 |
Why?
| | Disease Susceptibility | 3 | 2018 | 351 | 0.230 |
Why?
| | Soft Tissue Infections | 1 | 2025 | 41 | 0.230 |
Why?
| | Sacroiliac Joint | 1 | 2025 | 34 | 0.230 |
Why?
| | Neurofibromatosis 1 | 1 | 2025 | 55 | 0.230 |
Why?
| | Myocardial Infarction | 1 | 2012 | 1066 | 0.230 |
Why?
| | Program Evaluation | 3 | 2020 | 919 | 0.220 |
Why?
| | Infant | 16 | 2016 | 9820 | 0.220 |
Why?
| | Epidemiologic Research Design | 3 | 2004 | 28 | 0.220 |
Why?
| | Radiography, Thoracic | 1 | 2006 | 179 | 0.220 |
Why?
| | Laryngeal Neoplasms | 2 | 2004 | 34 | 0.220 |
Why?
| | Age Distribution | 5 | 2013 | 396 | 0.220 |
Why?
| | Airports | 1 | 2024 | 3 | 0.220 |
Why?
| | Radiation, Ionizing | 1 | 2024 | 80 | 0.210 |
Why?
| | Lactoferrin | 3 | 1999 | 38 | 0.210 |
Why?
| | Infant, Newborn | 15 | 2016 | 6270 | 0.210 |
Why?
| | Mutagens | 1 | 2004 | 26 | 0.210 |
Why?
| | Hepatitis B | 1 | 2004 | 67 | 0.210 |
Why?
| | Health Personnel | 3 | 2022 | 727 | 0.210 |
Why?
| | Health Services Research | 2 | 2014 | 401 | 0.210 |
Why?
| | Cleft Palate | 2 | 2015 | 81 | 0.210 |
Why?
| | Rhinovirus | 1 | 2004 | 58 | 0.210 |
Why?
| | Epidemiological Monitoring | 7 | 2008 | 67 | 0.210 |
Why?
| | Cross-Sectional Studies | 18 | 2024 | 5653 | 0.210 |
Why?
| | Mortality, Premature | 2 | 2024 | 13 | 0.210 |
Why?
| | National Health Programs | 2 | 2019 | 20 | 0.210 |
Why?
| | Glycerol | 1 | 2024 | 90 | 0.210 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2025 | 205 | 0.200 |
Why?
| | Vulnerable Populations | 2 | 2015 | 170 | 0.200 |
Why?
| | Time | 2 | 2003 | 87 | 0.200 |
Why?
| | Environment Design | 1 | 2003 | 26 | 0.200 |
Why?
| | Liability, Legal | 2 | 2006 | 42 | 0.200 |
Why?
| | Medical Marijuana | 1 | 2025 | 124 | 0.200 |
Why?
| | Pregnancy | 11 | 2016 | 7035 | 0.200 |
Why?
| | Osteomyelitis | 1 | 2025 | 143 | 0.200 |
Why?
| | Brain Neoplasms | 2 | 2010 | 1282 | 0.200 |
Why?
| | Hypertension | 5 | 2012 | 1250 | 0.200 |
Why?
| | Logistic Models | 10 | 2016 | 2098 | 0.200 |
Why?
| | Germ-Line Mutation | 1 | 2004 | 168 | 0.200 |
Why?
| | Dust | 4 | 2007 | 99 | 0.200 |
Why?
| | Diabetes Complications | 1 | 2005 | 222 | 0.200 |
Why?
| | Bone Neoplasms | 1 | 2025 | 249 | 0.200 |
Why?
| | Fasting | 1 | 2005 | 283 | 0.190 |
Why?
| | Sensitivity and Specificity | 4 | 2016 | 1973 | 0.190 |
Why?
| | Travel | 1 | 2004 | 139 | 0.190 |
Why?
| | Weather | 5 | 2009 | 40 | 0.190 |
Why?
| | Disinfection | 1 | 2024 | 128 | 0.190 |
Why?
| | Databases as Topic | 4 | 2008 | 68 | 0.190 |
Why?
| | Reproducibility of Results | 6 | 2025 | 3345 | 0.190 |
Why?
| | Polonium | 3 | 1991 | 3 | 0.190 |
Why?
| | Electromagnetic Fields | 2 | 2014 | 38 | 0.190 |
Why?
| | Financial Support | 2 | 2016 | 17 | 0.180 |
Why?
| | California | 5 | 2025 | 457 | 0.180 |
Why?
| | Healthcare Disparities | 2 | 2020 | 674 | 0.180 |
Why?
| | Adrenal Cortex Hormones | 1 | 2005 | 501 | 0.180 |
Why?
| | Risk Management | 3 | 2008 | 91 | 0.180 |
Why?
| | Pfiesteria piscicida | 1 | 2001 | 1 | 0.180 |
Why?
| | Engineering | 1 | 2022 | 30 | 0.180 |
Why?
| | Shoulder Joint | 1 | 2024 | 177 | 0.180 |
Why?
| | Nickel | 4 | 2009 | 61 | 0.180 |
Why?
| | Protozoan Infections | 1 | 2001 | 11 | 0.180 |
Why?
| | Recurrence | 2 | 2019 | 1108 | 0.180 |
Why?
| | Policy Making | 4 | 2012 | 79 | 0.180 |
Why?
| | Analgesics | 1 | 2023 | 231 | 0.180 |
Why?
| | Lumbosacral Plexus | 1 | 2021 | 9 | 0.180 |
Why?
| | Estrogen Replacement Therapy | 1 | 2002 | 142 | 0.180 |
Why?
| | Diagnosis, Differential | 3 | 2026 | 1491 | 0.180 |
Why?
| | Baltimore | 5 | 2014 | 68 | 0.180 |
Why?
| | Gases | 2 | 2007 | 52 | 0.170 |
Why?
| | Pulmonary Fibrosis | 3 | 2000 | 389 | 0.170 |
Why?
| | Conflict of Interest | 1 | 2001 | 44 | 0.170 |
Why?
| | Plants, Toxic | 2 | 1998 | 19 | 0.170 |
Why?
| | Maximum Allowable Concentration | 2 | 2015 | 16 | 0.170 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2004 | 353 | 0.170 |
Why?
| | Hyperglycemia | 1 | 2005 | 365 | 0.170 |
Why?
| | Residence Characteristics | 4 | 2018 | 367 | 0.170 |
Why?
| | SEER Program | 2 | 2021 | 219 | 0.170 |
Why?
| | Bismuth | 2 | 1991 | 3 | 0.170 |
Why?
| | Receptors, Cell Surface | 2 | 2001 | 375 | 0.170 |
Why?
| | Reproduction | 2 | 2001 | 206 | 0.170 |
Why?
| | Extremities | 3 | 2024 | 140 | 0.170 |
Why?
| | Patient Admission | 3 | 2012 | 203 | 0.160 |
Why?
| | Social Determinants of Health | 1 | 2024 | 275 | 0.160 |
Why?
| | Confidentiality | 2 | 2019 | 71 | 0.160 |
Why?
| | Medicine | 1 | 2022 | 125 | 0.160 |
Why?
| | Poisson Distribution | 3 | 2012 | 76 | 0.160 |
Why?
| | Health Priorities | 4 | 2010 | 42 | 0.160 |
Why?
| | Competency-Based Education | 1 | 2020 | 75 | 0.160 |
Why?
| | Clinical Medicine | 1 | 2000 | 25 | 0.160 |
Why?
| | Follow-Up Studies | 10 | 2020 | 5222 | 0.160 |
Why?
| | Arachidonic Acid | 3 | 2001 | 107 | 0.160 |
Why?
| | Panama | 1 | 2019 | 14 | 0.150 |
Why?
| | Minnesota | 3 | 2009 | 168 | 0.150 |
Why?
| | Anti-Inflammatory Agents | 1 | 2003 | 477 | 0.150 |
Why?
| | Talc | 1 | 2019 | 9 | 0.150 |
Why?
| | Carbon | 5 | 2009 | 204 | 0.150 |
Why?
| | Petroleum Pollution | 1 | 2019 | 10 | 0.150 |
Why?
| | Biodiversity | 1 | 2023 | 419 | 0.150 |
Why?
| | Public Health Surveillance | 1 | 2020 | 83 | 0.150 |
Why?
| | Animals | 18 | 2020 | 37328 | 0.150 |
Why?
| | Artificial Intelligence | 1 | 2023 | 342 | 0.150 |
Why?
| | Models, Theoretical | 5 | 2014 | 582 | 0.150 |
Why?
| | Mast Cells | 2 | 2001 | 148 | 0.150 |
Why?
| | Policy | 2 | 2021 | 146 | 0.150 |
Why?
| | Licensure | 1 | 2019 | 14 | 0.150 |
Why?
| | Peripheral Nerve Injuries | 1 | 2019 | 38 | 0.150 |
Why?
| | Authorship | 1 | 1999 | 44 | 0.150 |
Why?
| | Arsenic | 1 | 1999 | 63 | 0.150 |
Why?
| | Mental Health | 1 | 2025 | 756 | 0.150 |
Why?
| | Catholicism | 1 | 2018 | 9 | 0.150 |
Why?
| | HIV Infections | 5 | 2016 | 2981 | 0.140 |
Why?
| | Molecular Epidemiology | 2 | 2009 | 72 | 0.140 |
Why?
| | Disasters | 3 | 2018 | 99 | 0.140 |
Why?
| | Weight Gain | 1 | 2002 | 536 | 0.140 |
Why?
| | Prognosis | 8 | 2026 | 4080 | 0.140 |
Why?
| | Emergency Service, Hospital | 2 | 2009 | 2210 | 0.140 |
Why?
| | Liver Neoplasms | 1 | 2004 | 741 | 0.140 |
Why?
| | Social Responsibility | 1 | 2018 | 52 | 0.140 |
Why?
| | Human Migration | 1 | 2018 | 25 | 0.140 |
Why?
| | Veterans | 1 | 2010 | 1519 | 0.140 |
Why?
| | Greenhouse Gases | 1 | 2018 | 8 | 0.140 |
Why?
| | Transferrin | 1 | 1998 | 50 | 0.140 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 1999 | 167 | 0.140 |
Why?
| | Glycine | 1 | 2019 | 187 | 0.140 |
Why?
| | Models, Biological | 4 | 2015 | 1810 | 0.140 |
Why?
| | Writing | 1 | 1999 | 99 | 0.140 |
Why?
| | Radiobiology | 1 | 2017 | 6 | 0.140 |
Why?
| | Poverty | 3 | 2023 | 527 | 0.140 |
Why?
| | Frail Elderly | 1 | 1999 | 132 | 0.140 |
Why?
| | Restaurants | 3 | 2012 | 22 | 0.140 |
Why?
| | Health Communication | 1 | 2018 | 48 | 0.140 |
Why?
| | Cross-Over Studies | 4 | 2022 | 578 | 0.140 |
Why?
| | Sleep | 3 | 2018 | 882 | 0.140 |
Why?
| | Ferritins | 4 | 1998 | 66 | 0.130 |
Why?
| | Industry | 2 | 2010 | 41 | 0.130 |
Why?
| | Antioxidants | 1 | 2001 | 593 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 277 | 0.130 |
Why?
| | Cross-Cultural Comparison | 3 | 1994 | 85 | 0.130 |
Why?
| | Heating | 3 | 2007 | 18 | 0.130 |
Why?
| | Imaging, Three-Dimensional | 1 | 2021 | 565 | 0.130 |
Why?
| | Air | 2 | 2010 | 43 | 0.130 |
Why?
| | Pulmonary Medicine | 2 | 2017 | 83 | 0.130 |
Why?
| | Bronchitis, Chronic | 1 | 2017 | 24 | 0.130 |
Why?
| | Public Health Administration | 1 | 2018 | 74 | 0.130 |
Why?
| | Economics | 1 | 2017 | 11 | 0.130 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2022 | 2529 | 0.130 |
Why?
| | Publication Bias | 2 | 2008 | 17 | 0.130 |
Why?
| | Periodicals as Topic | 1 | 1999 | 198 | 0.130 |
Why?
| | Occupational Health | 1 | 1999 | 202 | 0.130 |
Why?
| | Social Class | 3 | 2017 | 269 | 0.130 |
Why?
| | Universities | 2 | 2016 | 450 | 0.130 |
Why?
| | Environment | 2 | 2012 | 342 | 0.130 |
Why?
| | Radiation Dosage | 4 | 2007 | 189 | 0.130 |
Why?
| | Algorithms | 5 | 2026 | 1764 | 0.130 |
Why?
| | Dioxins | 1 | 1996 | 7 | 0.120 |
Why?
| | Stem Cell Factor | 1 | 1996 | 17 | 0.120 |
Why?
| | Ferric Compounds | 1 | 1997 | 55 | 0.120 |
Why?
| | Iran | 1 | 2016 | 44 | 0.120 |
Why?
| | Mental Disorders | 1 | 2025 | 1133 | 0.120 |
Why?
| | Zinc | 1 | 1999 | 298 | 0.120 |
Why?
| | North America | 4 | 2021 | 304 | 0.120 |
Why?
| | Peer Influence | 1 | 2016 | 14 | 0.120 |
Why?
| | Product Labeling | 1 | 2016 | 10 | 0.120 |
Why?
| | Eating | 1 | 2018 | 393 | 0.120 |
Why?
| | Capacity Building | 1 | 2016 | 59 | 0.120 |
Why?
| | Polycyclic Aromatic Hydrocarbons | 2 | 2007 | 27 | 0.120 |
Why?
| | Xenobiotics | 1 | 1995 | 32 | 0.120 |
Why?
| | Emigrants and Immigrants | 1 | 2018 | 148 | 0.120 |
Why?
| | Coinfection | 1 | 2016 | 131 | 0.120 |
Why?
| | Socioeconomic Factors | 5 | 2016 | 1311 | 0.110 |
Why?
| | Polychlorinated Dibenzodioxins | 2 | 2010 | 8 | 0.110 |
Why?
| | Air Pollution, Radioactive | 1 | 1994 | 2 | 0.110 |
Why?
| | Asia | 4 | 2024 | 67 | 0.110 |
Why?
| | Schools, Medical | 1 | 2016 | 154 | 0.110 |
Why?
| | Internationality | 1 | 2016 | 156 | 0.110 |
Why?
| | Primary Health Care | 1 | 2005 | 1757 | 0.110 |
Why?
| | Cooking | 2 | 2023 | 67 | 0.110 |
Why?
| | Insurance, Health | 2 | 2009 | 296 | 0.110 |
Why?
| | Motivation | 1 | 2020 | 600 | 0.110 |
Why?
| | Sleep Apnea, Obstructive | 2 | 2014 | 318 | 0.110 |
Why?
| | Radiation Effects | 2 | 2004 | 7 | 0.110 |
Why?
| | Oxidants | 1 | 1994 | 104 | 0.110 |
Why?
| | PubMed | 1 | 2014 | 11 | 0.110 |
Why?
| | Latin America | 1 | 2014 | 89 | 0.110 |
Why?
| | Pelvic Bones | 1 | 2016 | 129 | 0.100 |
Why?
| | Review Literature as Topic | 1 | 2014 | 49 | 0.100 |
Why?
| | Silicosis | 1 | 1994 | 28 | 0.100 |
Why?
| | Temperature | 5 | 2005 | 668 | 0.100 |
Why?
| | Cleft Lip | 1 | 2014 | 65 | 0.100 |
Why?
| | Mastectomy, Segmental | 1 | 1994 | 101 | 0.100 |
Why?
| | Ganglionic Stimulants | 2 | 2015 | 15 | 0.100 |
Why?
| | Mucus | 1 | 1994 | 78 | 0.100 |
Why?
| | Drug Synergism | 1 | 2014 | 367 | 0.100 |
Why?
| | Breast | 1 | 1994 | 155 | 0.100 |
Why?
| | Health Plan Implementation | 1 | 2014 | 142 | 0.100 |
Why?
| | Community Networks | 1 | 2013 | 57 | 0.100 |
Why?
| | Analysis of Variance | 4 | 2009 | 1312 | 0.100 |
Why?
| | Benzene | 2 | 2023 | 18 | 0.100 |
Why?
| | Bone and Bones | 1 | 2016 | 312 | 0.100 |
Why?
| | History, 19th Century | 1 | 2013 | 58 | 0.100 |
Why?
| | Taxes | 2 | 2010 | 15 | 0.100 |
Why?
| | Iron | 4 | 1999 | 324 | 0.100 |
Why?
| | Greenhouse Effect | 3 | 2001 | 10 | 0.100 |
Why?
| | American Cancer Society | 2 | 2009 | 5 | 0.100 |
Why?
| | Administration, Inhalation | 2 | 2005 | 594 | 0.100 |
Why?
| | Zonula Occludens-1 Protein | 1 | 2012 | 17 | 0.100 |
Why?
| | Names | 1 | 2012 | 14 | 0.100 |
Why?
| | Apoptosis Regulatory Proteins | 2 | 2024 | 188 | 0.100 |
Why?
| | Snoring | 2 | 2010 | 18 | 0.090 |
Why?
| | Local Government | 1 | 2012 | 26 | 0.090 |
Why?
| | Calpain | 1 | 2012 | 60 | 0.090 |
Why?
| | Inflammation | 4 | 2023 | 2840 | 0.090 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 1125 | 0.090 |
Why?
| | Program Development | 1 | 2014 | 364 | 0.090 |
Why?
| | Sodium, Dietary | 1 | 2012 | 38 | 0.090 |
Why?
| | Allergens | 2 | 2014 | 399 | 0.090 |
Why?
| | United Kingdom | 2 | 2006 | 321 | 0.090 |
Why?
| | Nonlinear Dynamics | 2 | 2003 | 92 | 0.090 |
Why?
| | Feeding Behavior | 1 | 1998 | 679 | 0.090 |
Why?
| | TRPM Cation Channels | 1 | 2012 | 75 | 0.090 |
Why?
| | Sampling Studies | 2 | 2006 | 102 | 0.090 |
Why?
| | Diet, Carbohydrate-Restricted | 2 | 2022 | 37 | 0.090 |
Why?
| | Maryland | 2 | 2008 | 60 | 0.090 |
Why?
| | Public Facilities | 2 | 2008 | 5 | 0.090 |
Why?
| | Eosinophils | 1 | 2014 | 319 | 0.090 |
Why?
| | Pennsylvania | 5 | 2006 | 135 | 0.090 |
Why?
| | Body Temperature | 2 | 2002 | 224 | 0.090 |
Why?
| | Ethiopia | 2 | 2021 | 40 | 0.090 |
Why?
| | Sick Building Syndrome | 1 | 2011 | 4 | 0.090 |
Why?
| | Students, Medical | 1 | 2016 | 370 | 0.090 |
Why?
| | Communicable Diseases | 2 | 2011 | 162 | 0.090 |
Why?
| | Crime | 1 | 2011 | 60 | 0.080 |
Why?
| | Printing | 1 | 2010 | 5 | 0.080 |
Why?
| | Manufactured Materials | 1 | 2010 | 8 | 0.080 |
Why?
| | Self Report | 4 | 2017 | 859 | 0.080 |
Why?
| | Cell Line, Transformed | 3 | 1999 | 145 | 0.080 |
Why?
| | Pregnancy, Ectopic | 1 | 1991 | 54 | 0.080 |
Why?
| | Defoliants, Chemical | 1 | 2010 | 1 | 0.080 |
Why?
| | Agent Orange | 1 | 2010 | 2 | 0.080 |
Why?
| | 2,4,5-Trichlorophenoxyacetic Acid | 1 | 2010 | 2 | 0.080 |
Why?
| | Aging | 2 | 2002 | 1919 | 0.080 |
Why?
| | Maternal Welfare | 1 | 2010 | 20 | 0.080 |
Why?
| | 2,4-Dichlorophenoxyacetic Acid | 1 | 2010 | 13 | 0.080 |
Why?
| | Waist Circumference | 1 | 2010 | 134 | 0.080 |
Why?
| | Lung Diseases, Obstructive | 2 | 1988 | 43 | 0.080 |
Why?
| | Prostatic Neoplasms | 3 | 1996 | 1050 | 0.080 |
Why?
| | Curriculum | 2 | 2008 | 1035 | 0.080 |
Why?
| | Suicide | 1 | 2017 | 669 | 0.080 |
Why?
| | New York City | 2 | 2007 | 88 | 0.080 |
Why?
| | Water Pollution | 2 | 2018 | 9 | 0.080 |
Why?
| | Developed Countries | 1 | 2010 | 38 | 0.080 |
Why?
| | Disclosure | 1 | 2010 | 82 | 0.080 |
Why?
| | Legislation as Topic | 1 | 2009 | 5 | 0.080 |
Why?
| | Carcinoma | 2 | 2007 | 230 | 0.080 |
Why?
| | Legislation, Medical | 1 | 2009 | 11 | 0.080 |
Why?
| | Radioactive Pollutants | 1 | 1989 | 1 | 0.080 |
Why?
| | Medical Record Linkage | 2 | 2013 | 68 | 0.080 |
Why?
| | Monte Carlo Method | 1 | 2009 | 150 | 0.080 |
Why?
| | Food Contamination, Radioactive | 1 | 1989 | 1 | 0.080 |
Why?
| | Birth Weight | 1 | 2012 | 511 | 0.080 |
Why?
| | Radioisotopes | 1 | 1989 | 33 | 0.080 |
Why?
| | Survival Rate | 5 | 2009 | 1979 | 0.080 |
Why?
| | Cooperative Behavior | 2 | 2018 | 456 | 0.070 |
Why?
| | Models, Econometric | 1 | 2009 | 36 | 0.070 |
Why?
| | Costs and Cost Analysis | 1 | 2010 | 219 | 0.070 |
Why?
| | Gallbladder Diseases | 1 | 1988 | 11 | 0.070 |
Why?
| | Phospholipases A | 2 | 2001 | 101 | 0.070 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2009 | 134 | 0.070 |
Why?
| | New York | 2 | 2010 | 128 | 0.070 |
Why?
| | ROC Curve | 1 | 2010 | 594 | 0.070 |
Why?
| | Health Education | 3 | 2014 | 360 | 0.070 |
Why?
| | Nicotinic Antagonists | 1 | 2008 | 36 | 0.070 |
Why?
| | Interdisciplinary Communication | 2 | 2011 | 190 | 0.070 |
Why?
| | Epithelial Cells | 6 | 2000 | 1105 | 0.070 |
Why?
| | Decision Making | 3 | 2010 | 949 | 0.070 |
Why?
| | Students, Public Health | 1 | 2008 | 1 | 0.070 |
Why?
| | DNA Damage | 2 | 2004 | 430 | 0.070 |
Why?
| | Computer Simulation | 2 | 2009 | 1009 | 0.070 |
Why?
| | Nutrition Surveys | 2 | 2012 | 280 | 0.070 |
Why?
| | Dyspnea | 3 | 2024 | 258 | 0.070 |
Why?
| | Cells, Cultured | 6 | 2012 | 4149 | 0.070 |
Why?
| | Signal Transduction | 3 | 2003 | 5116 | 0.070 |
Why?
| | Pregnancy Outcome | 1 | 1991 | 453 | 0.070 |
Why?
| | Epidemiologic Factors | 2 | 2002 | 10 | 0.070 |
Why?
| | Bone Marrow Cells | 2 | 2001 | 316 | 0.070 |
Why?
| | Bronchial Hyperreactivity | 1 | 2008 | 102 | 0.070 |
Why?
| | Spectroscopy, Fourier Transform Infrared | 1 | 2007 | 87 | 0.070 |
Why?
| | Financing, Government | 2 | 2004 | 49 | 0.070 |
Why?
| | Coal Ash | 4 | 2000 | 8 | 0.070 |
Why?
| | Cardiovascular System | 1 | 2009 | 137 | 0.070 |
Why?
| | Predictive Value of Tests | 3 | 2010 | 2069 | 0.070 |
Why?
| | Rescue Work | 1 | 2007 | 11 | 0.070 |
Why?
| | Menopause | 2 | 2002 | 317 | 0.070 |
Why?
| | Polysomnography | 5 | 2009 | 240 | 0.070 |
Why?
| | Overweight | 2 | 2016 | 589 | 0.070 |
Why?
| | Automobile Driving | 1 | 2009 | 152 | 0.070 |
Why?
| | Delivery of Health Care | 1 | 2014 | 948 | 0.070 |
Why?
| | Insurance Coverage | 1 | 2009 | 239 | 0.070 |
Why?
| | Genome-Wide Association Study | 2 | 2014 | 1408 | 0.060 |
Why?
| | Tars | 1 | 2006 | 5 | 0.060 |
Why?
| | Schools, Public Health | 1 | 2006 | 4 | 0.060 |
Why?
| | Poland | 1 | 2006 | 35 | 0.060 |
Why?
| | Chromatography, Gas | 1 | 2006 | 32 | 0.060 |
Why?
| | Cost-Benefit Analysis | 1 | 2009 | 612 | 0.060 |
Why?
| | Forced Expiratory Volume | 3 | 2016 | 483 | 0.060 |
Why?
| | Multivariate Analysis | 5 | 2009 | 1505 | 0.060 |
Why?
| | Quality Improvement | 1 | 2015 | 1241 | 0.060 |
Why?
| | Energy Intake | 2 | 2001 | 510 | 0.060 |
Why?
| | Geography | 2 | 2008 | 197 | 0.060 |
Why?
| | Survival Analysis | 2 | 2004 | 1322 | 0.060 |
Why?
| | NF-kappa B | 3 | 2001 | 684 | 0.060 |
Why?
| | Biomass | 1 | 2007 | 113 | 0.060 |
Why?
| | Sulfur Dioxide | 4 | 2001 | 13 | 0.060 |
Why?
| | Practice Guidelines as Topic | 3 | 2017 | 1546 | 0.060 |
Why?
| | Cattle | 1 | 1989 | 982 | 0.060 |
Why?
| | Single Person | 1 | 1986 | 7 | 0.060 |
Why?
| | Statistics, Nonparametric | 2 | 2009 | 432 | 0.060 |
Why?
| | Students | 3 | 2016 | 644 | 0.060 |
Why?
| | Gift Giving | 1 | 2006 | 9 | 0.060 |
Why?
| | Fires | 1 | 2007 | 88 | 0.060 |
Why?
| | ErbB Receptors | 1 | 2009 | 612 | 0.060 |
Why?
| | Sleep Stages | 1 | 2006 | 76 | 0.060 |
Why?
| | Cough | 1 | 2007 | 133 | 0.060 |
Why?
| | Health Status | 2 | 2020 | 822 | 0.060 |
Why?
| | Computer-Assisted Instruction | 1 | 2006 | 68 | 0.060 |
Why?
| | Models, Educational | 1 | 2006 | 95 | 0.060 |
Why?
| | Meta-Analysis as Topic | 1 | 2006 | 168 | 0.060 |
Why?
| | Thinness | 1 | 2006 | 96 | 0.060 |
Why?
| | Biological Specimen Banks | 1 | 2006 | 98 | 0.060 |
Why?
| | Interinstitutional Relations | 1 | 2006 | 49 | 0.060 |
Why?
| | Consensus | 1 | 2008 | 538 | 0.060 |
Why?
| | Bioterrorism | 1 | 2006 | 31 | 0.060 |
Why?
| | Peripheral Arterial Disease | 1 | 2012 | 491 | 0.060 |
Why?
| | Endothelium, Vascular | 1 | 2012 | 943 | 0.060 |
Why?
| | United States Department of Veterans Affairs | 1 | 2010 | 711 | 0.060 |
Why?
| | Education, Distance | 1 | 2006 | 54 | 0.060 |
Why?
| | Behavior, Addictive | 1 | 2006 | 89 | 0.060 |
Why?
| | Rats | 4 | 1998 | 5556 | 0.060 |
Why?
| | Interviews as Topic | 4 | 2010 | 839 | 0.060 |
Why?
| | Communicable Disease Control | 1 | 2006 | 86 | 0.060 |
Why?
| | Goals | 1 | 2007 | 177 | 0.060 |
Why?
| | Hepatitis B Surface Antigens | 1 | 2004 | 21 | 0.060 |
Why?
| | Deferoxamine | 3 | 1999 | 26 | 0.060 |
Why?
| | Mexican Americans | 2 | 2018 | 112 | 0.060 |
Why?
| | Longitudinal Studies | 3 | 2016 | 2929 | 0.050 |
Why?
| | Financing, Organized | 1 | 2004 | 35 | 0.050 |
Why?
| | Uruguay | 1 | 2004 | 2 | 0.050 |
Why?
| | Paraguay | 1 | 2004 | 3 | 0.050 |
Why?
| | Stroke | 1 | 2013 | 1199 | 0.050 |
Why?
| | Disaster Planning | 1 | 2006 | 96 | 0.050 |
Why?
| | Immunohistochemistry | 2 | 1999 | 1724 | 0.050 |
Why?
| | Costa Rica | 1 | 2004 | 18 | 0.050 |
Why?
| | Glomerular Filtration Rate | 1 | 2008 | 755 | 0.050 |
Why?
| | Argentina | 1 | 2004 | 28 | 0.050 |
Why?
| | Chile | 1 | 2004 | 24 | 0.050 |
Why?
| | Spermatogonia | 1 | 2004 | 14 | 0.050 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2015 | 641 | 0.050 |
Why?
| | Observer Variation | 1 | 2025 | 356 | 0.050 |
Why?
| | Tandem Repeat Sequences | 1 | 2004 | 20 | 0.050 |
Why?
| | Diet Surveys | 1 | 1984 | 91 | 0.050 |
Why?
| | No-Observed-Adverse-Effect Level | 1 | 2004 | 6 | 0.050 |
Why?
| | Electroencephalography | 1 | 2007 | 522 | 0.050 |
Why?
| | Peru | 1 | 2004 | 61 | 0.050 |
Why?
| | Diet | 4 | 2003 | 1277 | 0.050 |
Why?
| | Uganda | 1 | 2024 | 86 | 0.050 |
Why?
| | Picornaviridae | 1 | 2004 | 20 | 0.050 |
Why?
| | Bronchodilator Agents | 1 | 2005 | 196 | 0.050 |
Why?
| | Mentors | 2 | 2003 | 213 | 0.050 |
Why?
| | Aircraft | 1 | 2004 | 22 | 0.050 |
Why?
| | Shoulder Pain | 1 | 2024 | 32 | 0.050 |
Why?
| | Nose Diseases | 1 | 2004 | 18 | 0.050 |
Why?
| | Ear Diseases | 1 | 2004 | 17 | 0.050 |
Why?
| | Propylene Glycols | 1 | 2024 | 28 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2004 | 74 | 0.050 |
Why?
| | Aerospace Medicine | 1 | 2004 | 35 | 0.050 |
Why?
| | Sugars | 1 | 2024 | 42 | 0.050 |
Why?
| | Picornaviridae Infections | 1 | 2004 | 51 | 0.050 |
Why?
| | Saskatchewan | 1 | 2003 | 8 | 0.050 |
Why?
| | Decision Support Techniques | 1 | 2008 | 433 | 0.050 |
Why?
| | Shoulder | 1 | 2024 | 93 | 0.050 |
Why?
| | Nasal Mucosa | 1 | 2004 | 111 | 0.050 |
Why?
| | Fourier Analysis | 1 | 2003 | 40 | 0.050 |
Why?
| | Observation | 1 | 2003 | 56 | 0.050 |
Why?
| | Chicago | 1 | 2003 | 62 | 0.050 |
Why?
| | Probability | 2 | 2003 | 307 | 0.050 |
Why?
| | Food | 1 | 1984 | 160 | 0.050 |
Why?
| | Free Radical Scavengers | 4 | 2012 | 86 | 0.050 |
Why?
| | Wakefulness | 1 | 2004 | 170 | 0.050 |
Why?
| | Computing Methodologies | 1 | 2003 | 3 | 0.050 |
Why?
| | Maps as Topic | 1 | 2003 | 5 | 0.050 |
Why?
| | Phosphotyrosine | 2 | 2000 | 40 | 0.050 |
Why?
| | Terminology as Topic | 1 | 1985 | 244 | 0.050 |
Why?
| | Coroners and Medical Examiners | 1 | 2022 | 8 | 0.050 |
Why?
| | Maternal-Fetal Exchange | 2 | 2015 | 170 | 0.050 |
Why?
| | Efficiency | 1 | 2003 | 101 | 0.050 |
Why?
| | Genomics | 1 | 2008 | 811 | 0.050 |
Why?
| | Washington | 1 | 2003 | 159 | 0.050 |
Why?
| | Neoplasm Staging | 2 | 2021 | 1397 | 0.050 |
Why?
| | Geographic Information Systems | 1 | 2003 | 45 | 0.050 |
Why?
| | Income | 2 | 1994 | 198 | 0.050 |
Why?
| | Body Constitution | 1 | 2002 | 54 | 0.050 |
Why?
| | Steroids | 1 | 2003 | 163 | 0.050 |
Why?
| | Sleep Wake Disorders | 1 | 2006 | 305 | 0.050 |
Why?
| | Nitrosamines | 2 | 2012 | 9 | 0.050 |
Why?
| | Carbon Dioxide | 1 | 2004 | 241 | 0.050 |
Why?
| | Peer Group | 1 | 2004 | 248 | 0.050 |
Why?
| | Macrophages, Alveolar | 2 | 1997 | 372 | 0.050 |
Why?
| | Epidemiologic Measurements | 1 | 2001 | 1 | 0.050 |
Why?
| | Chi-Square Distribution | 2 | 2006 | 526 | 0.050 |
Why?
| | Joint Instability | 1 | 2024 | 171 | 0.050 |
Why?
| | Toxins, Biological | 1 | 2001 | 12 | 0.050 |
Why?
| | Chelating Agents | 2 | 1999 | 73 | 0.050 |
Why?
| | Internet | 1 | 2006 | 683 | 0.040 |
Why?
| | Invertebrates | 1 | 2001 | 24 | 0.040 |
Why?
| | France | 1 | 2021 | 38 | 0.040 |
Why?
| | Philadelphia | 2 | 1998 | 53 | 0.040 |
Why?
| | Schizophrenia | 1 | 2025 | 440 | 0.040 |
Why?
| | Vitamin A | 3 | 1987 | 56 | 0.040 |
Why?
| | Patient Acceptance of Health Care | 1 | 1988 | 874 | 0.040 |
Why?
| | Likelihood Functions | 1 | 2001 | 143 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2008 | 11216 | 0.040 |
Why?
| | Sinusitis | 1 | 2004 | 239 | 0.040 |
Why?
| | Fishes | 1 | 2001 | 109 | 0.040 |
Why?
| | Food Chain | 1 | 2001 | 46 | 0.040 |
Why?
| | Germany | 1 | 2021 | 132 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2023 | 416 | 0.040 |
Why?
| | Population Dynamics | 1 | 2001 | 153 | 0.040 |
Why?
| | Pilot Projects | 1 | 2006 | 1820 | 0.040 |
Why?
| | Double-Blind Method | 2 | 2016 | 1992 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2002 | 771 | 0.040 |
Why?
| | Postmenopause | 1 | 2002 | 369 | 0.040 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2010 | 1395 | 0.040 |
Why?
| | Mathematics | 1 | 2000 | 103 | 0.040 |
Why?
| | Respiratory Hypersensitivity | 1 | 2000 | 68 | 0.040 |
Why?
| | Receptors, Progesterone | 1 | 2002 | 337 | 0.040 |
Why?
| | Stem Cells | 1 | 2004 | 604 | 0.040 |
Why?
| | Chromosome Deletion | 2 | 1997 | 118 | 0.040 |
Why?
| | Drug Interactions | 2 | 2003 | 404 | 0.040 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 1999 | 44 | 0.040 |
Why?
| | Protein Synthesis Inhibitors | 1 | 1999 | 46 | 0.040 |
Why?
| | Smoking Water Pipes | 1 | 2019 | 9 | 0.040 |
Why?
| | Health Status Indicators | 2 | 2000 | 161 | 0.040 |
Why?
| | Receptors, Estrogen | 1 | 2002 | 412 | 0.040 |
Why?
| | Bibliometrics | 1 | 1999 | 59 | 0.040 |
Why?
| | Culture Media | 1 | 1999 | 163 | 0.040 |
Why?
| | Infant, Low Birth Weight | 1 | 1999 | 145 | 0.040 |
Why?
| | Religious Personnel | 1 | 2018 | 1 | 0.040 |
Why?
| | Fossil Fuels | 2 | 2001 | 10 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2000 | 301 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 1998 | 633 | 0.040 |
Why?
| | Heart Rate | 1 | 2002 | 835 | 0.040 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2000 | 232 | 0.040 |
Why?
| | Activities of Daily Living | 2 | 1993 | 429 | 0.040 |
Why?
| | Maternal Age | 1 | 1998 | 128 | 0.040 |
Why?
| | Acculturation | 1 | 2018 | 53 | 0.030 |
Why?
| | Copper | 1 | 1998 | 115 | 0.030 |
Why?
| | Anthropometry | 1 | 2018 | 208 | 0.030 |
Why?
| | DNA Adducts | 1 | 1997 | 16 | 0.030 |
Why?
| | Benzo(a)pyrene | 1 | 1997 | 8 | 0.030 |
Why?
| | Mice | 4 | 2008 | 17969 | 0.030 |
Why?
| | Clinical Competence | 1 | 2025 | 1210 | 0.030 |
Why?
| | Lactation | 1 | 1998 | 190 | 0.030 |
Why?
| | Arizona | 2 | 2006 | 81 | 0.030 |
Why?
| | Stakeholder Participation | 1 | 2018 | 80 | 0.030 |
Why?
| | Interleukin-6 | 2 | 1998 | 775 | 0.030 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 99 | 0.030 |
Why?
| | Weight Loss | 1 | 2022 | 794 | 0.030 |
Why?
| | Injury Severity Score | 1 | 2019 | 570 | 0.030 |
Why?
| | HIV Seronegativity | 1 | 1996 | 30 | 0.030 |
Why?
| | Marriage | 3 | 1987 | 122 | 0.030 |
Why?
| | Multilevel Analysis | 1 | 2016 | 36 | 0.030 |
Why?
| | Social Support | 2 | 1993 | 629 | 0.030 |
Why?
| | Silicon Dioxide | 1 | 1997 | 118 | 0.030 |
Why?
| | Mice, Inbred CBA | 1 | 1996 | 55 | 0.030 |
Why?
| | Body Weight | 1 | 2021 | 992 | 0.030 |
Why?
| | Chemical Industry | 1 | 1996 | 9 | 0.030 |
Why?
| | Phospholipases A2 | 1 | 1996 | 81 | 0.030 |
Why?
| | New Zealand | 1 | 2016 | 55 | 0.030 |
Why?
| | Needs Assessment | 1 | 1999 | 388 | 0.030 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 1996 | 36 | 0.030 |
Why?
| | Head and Neck Neoplasms | 1 | 2001 | 557 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 1998 | 367 | 0.030 |
Why?
| | Acetylcysteine | 2 | 2012 | 144 | 0.030 |
Why?
| | South Africa | 1 | 2016 | 200 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2006 | 4414 | 0.030 |
Why?
| | Government Agencies | 1 | 1995 | 15 | 0.030 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2016 | 99 | 0.030 |
Why?
| | Eicosanoids | 1 | 1996 | 59 | 0.030 |
Why?
| | Genotype | 2 | 2014 | 1854 | 0.030 |
Why?
| | Africa, Central | 1 | 2015 | 6 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 1999 | 835 | 0.030 |
Why?
| | Indians, Central American | 1 | 2015 | 6 | 0.030 |
Why?
| | Asia, Southeastern | 1 | 2015 | 12 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 2 | 1998 | 2511 | 0.030 |
Why?
| | Central America | 1 | 2015 | 24 | 0.030 |
Why?
| | Indians, South American | 1 | 2015 | 22 | 0.030 |
Why?
| | Microscopy, Electron | 1 | 1996 | 414 | 0.030 |
Why?
| | Educational Status | 2 | 1996 | 463 | 0.030 |
Why?
| | Demography | 2 | 2000 | 296 | 0.030 |
Why?
| | Neoplasms, Experimental | 1 | 1996 | 174 | 0.030 |
Why?
| | Carrier Proteins | 1 | 1999 | 738 | 0.030 |
Why?
| | Homosexuality, Male | 1 | 1996 | 207 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 1997 | 334 | 0.030 |
Why?
| | Random Allocation | 1 | 1995 | 369 | 0.030 |
Why?
| | Carbohydrate Sequence | 1 | 1994 | 28 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1610 | 0.030 |
Why?
| | Animals, Newborn | 1 | 1997 | 866 | 0.030 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2015 | 114 | 0.030 |
Why?
| | Breast Feeding | 1 | 1998 | 441 | 0.030 |
Why?
| | Cytokines | 2 | 2003 | 2079 | 0.030 |
Why?
| | Linkage Disequilibrium | 1 | 2014 | 251 | 0.030 |
Why?
| | Population Density | 1 | 1994 | 98 | 0.030 |
Why?
| | Confidence Intervals | 2 | 2009 | 328 | 0.030 |
Why?
| | Patient Care Team | 1 | 1999 | 667 | 0.030 |
Why?
| | Occupations | 2 | 2000 | 51 | 0.030 |
Why?
| | Hydrocarbons | 1 | 1993 | 31 | 0.030 |
Why?
| | Mental Competency | 1 | 1993 | 25 | 0.030 |
Why?
| | Ecosystem | 1 | 2018 | 574 | 0.020 |
Why?
| | Heart Failure | 1 | 2006 | 2096 | 0.020 |
Why?
| | Fatty Acids | 1 | 1996 | 446 | 0.020 |
Why?
| | Membrane Proteins | 1 | 1999 | 1144 | 0.020 |
Why?
| | Health Services Needs and Demand | 1 | 2015 | 282 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 1996 | 1362 | 0.020 |
Why?
| | Family Health | 1 | 1994 | 194 | 0.020 |
Why?
| | Ecology | 1 | 1994 | 118 | 0.020 |
Why?
| | Vital Statistics | 1 | 1992 | 5 | 0.020 |
Why?
| | Transportation of Patients | 1 | 1993 | 65 | 0.020 |
Why?
| | Cadmium | 1 | 2012 | 68 | 0.020 |
Why?
| | Molecular Sequence Data | 2 | 1994 | 2911 | 0.020 |
Why?
| | Biopsy | 1 | 2015 | 1073 | 0.020 |
Why?
| | Electric Impedance | 1 | 2012 | 112 | 0.020 |
Why?
| | Permeability | 1 | 2012 | 163 | 0.020 |
Why?
| | Genes, p53 | 1 | 1992 | 68 | 0.020 |
Why?
| | Genes, ras | 1 | 1992 | 94 | 0.020 |
Why?
| | Physical Fitness | 1 | 1993 | 207 | 0.020 |
Why?
| | Africa | 1 | 2012 | 113 | 0.020 |
Why?
| | Drug Evaluation | 1 | 2011 | 79 | 0.020 |
Why?
| | Alleles | 1 | 2014 | 878 | 0.020 |
Why?
| | Otitis Media | 1 | 1994 | 168 | 0.020 |
Why?
| | Quality of Life | 1 | 2003 | 3024 | 0.020 |
Why?
| | Sick Leave | 1 | 2011 | 15 | 0.020 |
Why?
| | Safety | 1 | 1993 | 356 | 0.020 |
Why?
| | Colorado | 1 | 2021 | 4599 | 0.020 |
Why?
| | Recreation | 1 | 2011 | 26 | 0.020 |
Why?
| | HIV-1 | 1 | 2016 | 882 | 0.020 |
Why?
| | Survivors | 2 | 2004 | 501 | 0.020 |
Why?
| | Macrophages | 1 | 1998 | 1478 | 0.020 |
Why?
| | RNA, Messenger | 4 | 1998 | 2815 | 0.020 |
Why?
| | Dichlorodiphenyldichloroethane | 1 | 2009 | 1 | 0.020 |
Why?
| | Disease Progression | 1 | 1998 | 2808 | 0.020 |
Why?
| | Coffee | 1 | 2009 | 14 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2009 | 60 | 0.020 |
Why?
| | Mass Media | 1 | 2010 | 40 | 0.020 |
Why?
| | Health Services | 1 | 1990 | 116 | 0.020 |
Why?
| | Early Detection of Cancer | 1 | 2014 | 432 | 0.020 |
Why?
| | Reactive Oxygen Species | 1 | 2012 | 630 | 0.020 |
Why?
| | False Positive Reactions | 1 | 2009 | 122 | 0.020 |
Why?
| | Thorium | 1 | 1989 | 2 | 0.020 |
Why?
| | Ether | 1 | 2009 | 8 | 0.020 |
Why?
| | Radium | 1 | 1989 | 4 | 0.020 |
Why?
| | Metallurgy | 1 | 1989 | 9 | 0.020 |
Why?
| | Methylene Chloride | 1 | 2009 | 5 | 0.020 |
Why?
| | Colorectal Neoplasms | 2 | 1996 | 811 | 0.020 |
Why?
| | Rectal Neoplasms | 1 | 1990 | 152 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 1993 | 1090 | 0.020 |
Why?
| | Culture | 1 | 2010 | 129 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 1998 | 2600 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 1992 | 522 | 0.020 |
Why?
| | Pyridines | 1 | 2012 | 560 | 0.020 |
Why?
| | Taiwan | 1 | 2008 | 46 | 0.020 |
Why?
| | Death Certificates | 1 | 1988 | 30 | 0.020 |
Why?
| | Cell Differentiation | 1 | 1996 | 1983 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2016 | 2904 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2010 | 241 | 0.020 |
Why?
| | Liver | 1 | 1997 | 1821 | 0.020 |
Why?
| | Pregnancy Complications | 1 | 1994 | 577 | 0.020 |
Why?
| | Colonic Neoplasms | 1 | 1990 | 244 | 0.020 |
Why?
| | Industrial Waste | 1 | 2008 | 6 | 0.020 |
Why?
| | Ovalbumin | 1 | 2008 | 194 | 0.020 |
Why?
| | Welding | 1 | 1987 | 2 | 0.020 |
Why?
| | Government Programs | 1 | 2008 | 27 | 0.020 |
Why?
| | Paint | 1 | 1987 | 9 | 0.020 |
Why?
| | Texas | 1 | 1988 | 267 | 0.020 |
Why?
| | Risk Reduction Behavior | 1 | 2009 | 227 | 0.020 |
Why?
| | Forced Expiratory Flow Rates | 1 | 1987 | 10 | 0.020 |
Why?
| | Peak Expiratory Flow Rate | 1 | 1987 | 25 | 0.020 |
Why?
| | Schools | 1 | 2011 | 451 | 0.020 |
Why?
| | Conservation of Energy Resources | 1 | 2007 | 3 | 0.020 |
Why?
| | Behavior Therapy | 1 | 2010 | 282 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2014 | 2122 | 0.020 |
Why?
| | Physical Examination | 1 | 1988 | 243 | 0.020 |
Why?
| | Calcium | 1 | 2012 | 1175 | 0.020 |
Why?
| | Radiation Monitoring | 1 | 1986 | 15 | 0.020 |
Why?
| | Massachusetts | 1 | 2006 | 176 | 0.020 |
Why?
| | Attitude | 1 | 1988 | 257 | 0.020 |
Why?
| | Air Conditioning | 1 | 2006 | 6 | 0.020 |
Why?
| | HIV | 1 | 2007 | 248 | 0.010 |
Why?
| | Medical History Taking | 1 | 1986 | 117 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2012 | 1327 | 0.010 |
Why?
| | Arousal | 1 | 2006 | 158 | 0.010 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2007 | 278 | 0.010 |
Why?
| | Rural Population | 2 | 1987 | 602 | 0.010 |
Why?
| | Physicians | 1 | 1994 | 930 | 0.010 |
Why?
| | Electronic Health Records | 1 | 2013 | 1129 | 0.010 |
Why?
| | Statistics as Topic | 1 | 1986 | 298 | 0.010 |
Why?
| | beta Carotene | 1 | 1984 | 20 | 0.010 |
Why?
| | Dementia | 1 | 1988 | 269 | 0.010 |
Why?
| | Carotenoids | 1 | 1984 | 42 | 0.010 |
Why?
| | Nitrogen Oxides | 1 | 2004 | 54 | 0.010 |
Why?
| | X-Rays | 1 | 2003 | 31 | 0.010 |
Why?
| | Pneumoconiosis | 1 | 1984 | 20 | 0.010 |
Why?
| | Heart Conduction System | 1 | 2004 | 92 | 0.010 |
Why?
| | Biophysical Phenomena | 1 | 2003 | 68 | 0.010 |
Why?
| | Population | 1 | 2003 | 32 | 0.010 |
Why?
| | Gamma Rays | 1 | 2003 | 56 | 0.010 |
Why?
| | Biophysics | 1 | 2003 | 74 | 0.010 |
Why?
| | Oxyhemoglobins | 1 | 2003 | 24 | 0.010 |
Why?
| | Cell Line | 2 | 1998 | 2863 | 0.010 |
Why?
| | Databases, Factual | 1 | 2008 | 1449 | 0.010 |
Why?
| | Mothers | 1 | 2009 | 776 | 0.010 |
Why?
| | Training Support | 1 | 2002 | 36 | 0.010 |
Why?
| | Blood Pressure | 1 | 2009 | 1740 | 0.010 |
Why?
| | Receptors, Phospholipase A2 | 1 | 2001 | 1 | 0.010 |
Why?
| | Pharyngeal Neoplasms | 1 | 2001 | 5 | 0.010 |
Why?
| | Interleukin-3 | 1 | 2001 | 24 | 0.010 |
Why?
| | Annexin A5 | 1 | 2001 | 25 | 0.010 |
Why?
| | Polymerase Chain Reaction | 2 | 1997 | 1050 | 0.010 |
Why?
| | Vital Capacity | 1 | 2003 | 305 | 0.010 |
Why?
| | Oxidants, Photochemical | 1 | 2001 | 8 | 0.010 |
Why?
| | Food Contamination | 1 | 2001 | 54 | 0.010 |
Why?
| | Pancreatic Neoplasms | 1 | 2009 | 890 | 0.010 |
Why?
| | Lysophospholipids | 1 | 2001 | 73 | 0.010 |
Why?
| | Disease Transmission, Infectious | 1 | 2001 | 70 | 0.010 |
Why?
| | Mouth Neoplasms | 1 | 2001 | 89 | 0.010 |
Why?
| | Isoenzymes | 1 | 2001 | 296 | 0.010 |
Why?
| | Mutation | 1 | 1992 | 4006 | 0.010 |
Why?
| | Parents | 1 | 1989 | 1439 | 0.010 |
Why?
| | Immunoenzyme Techniques | 1 | 2000 | 206 | 0.010 |
Why?
| | Fungi | 1 | 2001 | 152 | 0.010 |
Why?
| | Agriculture | 1 | 2000 | 99 | 0.010 |
Why?
| | Melanoma | 2 | 1986 | 786 | 0.010 |
Why?
| | Extracellular Matrix | 1 | 2003 | 554 | 0.010 |
Why?
| | Reference Values | 1 | 2000 | 803 | 0.010 |
Why?
| | Ceruloplasmin | 1 | 1998 | 10 | 0.010 |
Why?
| | Protein Biosynthesis | 1 | 2001 | 439 | 0.010 |
Why?
| | Boston | 1 | 1978 | 91 | 0.010 |
Why?
| | Fuel Oils | 1 | 1998 | 2 | 0.010 |
Why?
| | Histocytochemistry | 1 | 1998 | 80 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2000 | 784 | 0.010 |
Why?
| | Utah | 1 | 1998 | 74 | 0.010 |
Why?
| | Receptors, Transferrin | 1 | 1998 | 28 | 0.010 |
Why?
| | Cell Survival | 1 | 2001 | 1123 | 0.010 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 1998 | 142 | 0.010 |
Why?
| | Software | 1 | 2003 | 675 | 0.010 |
Why?
| | Thiourea | 1 | 1997 | 41 | 0.010 |
Why?
| | Autoradiography | 1 | 1997 | 65 | 0.010 |
Why?
| | Blotting, Western | 1 | 2000 | 1220 | 0.010 |
Why?
| | Respiratory Mucosa | 1 | 2000 | 324 | 0.010 |
Why?
| | Intubation, Intratracheal | 1 | 2000 | 306 | 0.010 |
Why?
| | Interferons | 1 | 1998 | 194 | 0.010 |
Why?
| | Microsatellite Repeats | 1 | 1997 | 158 | 0.010 |
Why?
| | Sputum | 1 | 1978 | 310 | 0.010 |
Why?
| | Heterozygote | 1 | 1997 | 306 | 0.010 |
Why?
| | Interleukin-8 | 1 | 1997 | 268 | 0.010 |
Why?
| | Epithelium | 1 | 1997 | 311 | 0.010 |
Why?
| | Comorbidity | 1 | 2001 | 1671 | 0.010 |
Why?
| | Age of Onset | 1 | 1998 | 536 | 0.010 |
Why?
| | Heart Defects, Congenital | 1 | 2004 | 880 | 0.010 |
Why?
| | Transfection | 1 | 1998 | 932 | 0.010 |
Why?
| | Protein Binding | 1 | 2001 | 2233 | 0.010 |
Why?
| | Skin Neoplasms | 1 | 1982 | 851 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2001 | 1486 | 0.010 |
Why?
| | Polymorphism, Genetic | 1 | 1997 | 619 | 0.010 |
Why?
| | Pacific Islands | 1 | 1994 | 3 | 0.010 |
Why?
| | West Virginia | 1 | 1993 | 9 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 1998 | 1244 | 0.010 |
Why?
| | Apoptosis | 1 | 2001 | 2487 | 0.010 |
Why?
| | Platelet Activating Factor | 1 | 1992 | 47 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 1997 | 1220 | 0.010 |
Why?
| | Primary Prevention | 1 | 1994 | 202 | 0.010 |
Why?
| | Prostaglandins | 1 | 1992 | 97 | 0.010 |
Why?
| | Respiratory Function Tests | 1 | 1994 | 558 | 0.010 |
Why?
| | Codon | 1 | 1992 | 92 | 0.010 |
Why?
| | DNA, Neoplasm | 1 | 1992 | 159 | 0.010 |
Why?
| | DNA | 1 | 1998 | 1440 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 1992 | 1059 | 0.010 |
Why?
| | Base Sequence | 1 | 1992 | 2170 | 0.000 |
Why?
| | Cognition | 1 | 1996 | 1226 | 0.000 |
Why?
| | Carcinoma, Bronchogenic | 1 | 1986 | 20 | 0.000 |
Why?
| | Eye Neoplasms | 1 | 1986 | 28 | 0.000 |
Why?
| | Carcinoma, Small Cell | 1 | 1987 | 171 | 0.000 |
Why?
| | Feasibility Studies | 1 | 1990 | 1037 | 0.000 |
Why?
| | Retinoblastoma | 1 | 1986 | 40 | 0.000 |
Why?
| | Lymphoma | 1 | 1986 | 228 | 0.000 |
Why?
| | Self Disclosure | 1 | 1984 | 65 | 0.000 |
Why?
| | Leukemia | 1 | 1986 | 243 | 0.000 |
Why?
| | Neck | 1 | 1982 | 106 | 0.000 |
Why?
| | Head | 1 | 1982 | 118 | 0.000 |
Why?
|
|
Samet's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|